Editas Medicine Inc EDIT:NASDAQ

Last Price$10.72NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/18/22

Today's Change-0.91(7.82%)
Bid (Size)$10.50 (30)
Ask (Size)$10.71 (8)
Day Low / High$10.52 - 11.48
Volume1.4 M
 

View Biotechnology IndustryPeer Comparison as of 05/18/2022

 

Editas Medicine Inc ( NASDAQ )

Price: $10.72
Change: -0.91 (7.82%)
Volume: 1.4 M
4:00PM ET 5/18/2022
 
 

Organogenesis Holdings Inc ( NASDAQ )

Price: $5.46
Change: -0.46 (7.77%)
Volume: 1.2 M
4:00PM ET 5/18/2022
 
 

Avid Bioservices Inc ( NASDAQ )

Price: $11.63
Change: -0.71 (5.75%)
Volume: 787.3 K
4:00PM ET 5/18/2022
 
 

Deciphera Pharmaceuticals Inc ( NASDAQ )

Price: $10.91
Change: -0.52 (4.55%)
Volume: 1.3 M
4:00PM ET 5/18/2022
 
 

Alector Inc ( NASDAQ )

Price: $8.77
Change: -0.34 (3.73%)
Volume: 1.1 M
4:00PM ET 5/18/2022
 

Read more news Recent News

Editas Medicine Gets FDA Orphan Drug Designation for Blood Disorder Candidate
4:31AM ET 5/13/2022 MT Newswires

Editas Medicine (EDIT) said late Thursday the US Food and Drug Administration has granted orphan drug designation to EDIT-301 for the potential treatment...

--Morgan Stanley Lowers Editas Medicine's Price Target to $15 From $17, Underweight Rating Kept
12:45PM ET 5/09/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Oppenheimer Adjusts Editas Medicine Price Target to $28 From $55, Maintains Outperform Rating
12:07PM ET 5/05/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Editas Says EDIT-103 Shows Potential in Preclinical Data for Retinitis Pigmentosa; Shares Rise
3:07PM ET 5/04/2022 MT Newswires

Editas Medicine (EDIT) said Wednesday preclinical data for its experimental drug EDIT-103 to treat eye disease rhodopsin-associated autosomal dominant...

Company Profile

Business DescriptionEditas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA. View company web site for more details
Address11 Hurley Street
Cambridge, Massachusetts 02141
Phone+1.617.401.9000
Number of Employees133
Recent SEC Filing05/11/20224
Chairman, President & Chief Executive OfficerJames C. Mullen
Senior Vice President-OperationsHarry R. Gill
Chief Financial Officer, Treasurer & Executive VPMichelle Robertson
Chief Scientific Officer & Executive VPMark S. Shearman

Company Highlights

Price Open$11.25
Previous Close$10.72
52 Week Range$9.71 - 73.03
Market Capitalization$735.8 M
Shares Outstanding68.6 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.73
Beta vs. S&P 500N/A
Revenue$31.9 M
Net Profit Margin-721.60%
Return on Equity-32.88%

Analyst Ratings as of 04/14/2022

Buy
6
Overweight
1
Hold
7
Underweight
0
Sell
3
Consensus RecommendationConsensus Icon
Powered by Factset